Pennsylvania Society of Oncology & Hematology Welcomes Arturo Loiaza-Bonilla, MD, MSEd, as New President

September 30, 2020

Partners

Arturo Loaiza-Bonilla, MD, MSEd, FACP ascended to the presidency of the Pennsylvania Society of Oncology, albeit virtually, during the society’s Annual Scientific Conference held via ZOOM on September 25.


Arturo Loaiza-Bonilla, MD, MSEd, FACP, ascended to the presidency of the Pennsylvania Society of Oncology, albeit virtually, during the society’s Annual Scientific Conference held via ZOOM on September 25.

The Vice Chair of Medical Oncology and Medical Director of Clinical Research for Cancer Treatment Centers of America (CTCA) as well as its Gastrointestinal Program Director, and Senior Medical Director of Vidence, Dr. Loaiza-Bonilla practices at CTCA Philadelphia. He completed his undergraduate degree and medical degree at Universidad Nacional de Colombia in Bogotá, Columbia. An internship and residency in internal medicine followed at Johns Hopkins Harbor Hospital Center in Baltimore as did a fellowship in hematology and oncology at the University of Miami’s Miller School of Medicine and University of Miami’s Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital.

Prior to joining CTCA in 2017, Dr. Loaiza-Bonilla pursued a MSEd in medical education at the University of Pennsylvania while also serving as an assistant professor at the University’s Perelman School of Medicine. He also co-founded Massive Bio, a global industry leader in connecting patients to clinical trials. He continues to serve as its Chief Medical Advisor.

Board certified in medical oncology and hematology, Dr. Loaiza-Bonilla is an internationally renowned medical oncologist and researcher, having been published in numerous medical journals and oncology publications including ASCO’s Clinical Journal of Oncology and Google Scholar. He is a reviewer and counselor for several journals, special interest groups, panels and academic competitions and a principal investigator and co-investigator for many large oncology clinical trials.

In addition to the Pennsylvania Society of Oncology and Hematology, Dr. Loaiza-Bonilla has been a member and leader in the American Society of Hematology, American Society of Clinical Oncology and American Association of Cancer Research.

As president of PSOH, Dr. Loaiza-Bonilla intends to devote his two-year term to strengthening the organization as a resource, educator, and advocate for the oncology and hematology community.

###

The Pennsylvania Society of Oncology and Hematology is an organization of physicians and health care professionals devoted to the improvement of hematologic and oncologic care of patients since 1998. It strives to educate physicians and cancer care professionals about the latest clinical advances in cancer diagnosis, care and cancer-related issues; to set standards and guidelines for diagnosis and care of patients with hematologic and oncologic disorders; and to provide nonpartisan, multidisciplinary expert input to governmental bodies, legislators, third-party payers and other appropriate parties.